Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

# Washington, D.C. 20549

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)																
1. Name and Address of Reporting Person *- TRAVERSA SERGIO				2. Issuer Name and Ticker or Trading Symbol Actinium Pharmaceuticals, Inc. [ATNM]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O ACTINIUM PHARMACEUTICALS, INC, 275 MADISON AVENUE, 7TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 04/16/2016										tle below)		er (specify bel	ow)	
(Street) NEW YORK, NY 10016				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Be								f, or Ben	eficially Ow	ned			
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	Execution Date, if		3. Transaction Code (Instr. 8)		(A	4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)		of (D)	5. Amount of Securities Beneficial Owned Following Reported Transaction(s) (Instr. 3 and 4)		ted	Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Cod	e V	/ Ar	mount	(A) or (D)	Price					(I) (Instr. 4)	
Common	Stock		04/14/2016				P		2,	000	Λ	\$ 2.02	2,000			-	D	
Common Stock 04/15/2016			04/15/2016				P		1,	000		\$ 2.02	3,000			-	D	
1. Title of Derivative Security	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	e.g., puts.	, call	<b>ls, war</b> 5. Nur	rants,	cor form ired, I option 6. Dat Expira	ntaine m dis Dispos s, con te Exe	ed in the splays sed of, one of the sed of, one of the sed of the	his form a curre or Bene e secur	m are i ently v eficially	valid OME v Owned e and nt of	Red to B con	respo trol nun	nd unless t nber. 9. Number o	he	
(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8		Acqui (A) or Dispos (D)	ecurities (I Since I S		Securit	Amoun		(Instr. 5)	Beneficially Owned Following Reported Transaction(s (Instr. 4)	Security Direct ( or Indire	(Instr. 4)			
				Code	v	(A)	(D)	Date Exerci	isable	Expira Date	ation	Title	or Num of Share	ber				
Options to purchase common stock	\$ 1.99	04/15/2016		A		75,00	00	Ĺ	<u>1)</u>	04/15	5/2026	Comn Stoc	175.0	00 3	\$ 1.99	75,000	D	
Repor	ting O	wners																

B 4 0 N (All	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
TRAVERSA SERGIO C/O ACTINIUM PHARMACEUTICALS, INC 275 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10016	X						

#### **Signatures**

/s/ Sergio Traversa	04/18/2016
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it see}\ Instruction\ 6 for procedure.$ 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.